Benchmarked against rigorous Health Canada Natural and Non-prescription Health Products Directorate (NNHPD) parameters, our discovery platforms pinpoint high-potency bioactives for functional clinical trials.
Canada represents one of the most mature, quality-discerning natural health and botanical medicine markets globally. Navigating this sector requires bridging high biological variability with rigid statutory thresholds.
Under the Canadian Food and Drugs Act, all Natural Health Products (NHPs) sold in Canada require an eight-digit Natural Product Number (NPN). Screening natural active molecules must conform directly to NNHPD monographs, requiring validated chemical identity and toxicological threshold safety profiles before formulation approval.
Canadian brand manufacturers face rising climatic disruptions in key raw botanicals—from domestic Ginseng (Panax quinquefolius) to imported adaptogens. High-density screening allows Canadian formulators to identify parallel active molecular equivalents, stabilizing supply chains against batch variations.
Canadian consumers demand evidence-backed claims (e.g., cognitive support, immuno-modulation, metabolic health). Conducting comprehensive active ingredient screening upfront mitigates costly failures during downstream clinical verification and Site Licensing (SL) audits.
Integrating multi-dimensional chromatographic profiling, high-resolution mass spectrometry, and artificial intelligence models to predict pharmacological activity and bypass classical drug-discovery bottlenecks.
Harnessing modern chromatographic databases covering 400+ botanical species and 83 classic Traditional Herbal formulations to map targeted secondary metabolites.
Employing green SFE-CO2 and macroporous resin adsorption columns to enrich target active fractions without leaving halogenated or toxic solvent residues.
High-throughput enzyme assays (COX-2, AMPK, DPP-4) and macrophage inflammatory cascades to determine EC50 values rapidly for target indications.
Standardization via HPLC-QTOF and HPTLC fingerprints, accompanied by full Certificate of Analysis (CoA) documentation configured for Canadian regulatory filing.
How MedGence bridges the gap between early-stage laboratory discovery in Changsha and commercial-scale batch consistency delivered direct to Canadian ports and distribution hubs.
Our state-of-the-art facility integrates automated distributed control systems (DCS) monitoring temperature, vacuum pressure, and flow rates across our continuous countercurrent extraction lines. This industrial automation eliminates human batch variability and guarantees that the bioactivity identified during small-scale screening transfers uncompromised to 10-ton commercial production runs.
By retaining in-house research facilities alongside direct manufacturing controls, Canadian procurement teams eliminate middleman markup, achieving a 30% to 45% reduction in total development cycle time and substantial per-kilogram raw ingredient savings.
Schedule Technical ConsultationTraditional botanical extraction relies solely on crude yield ratios, frequently missing inactive or degraded compound fractions. Our targeted screening approach isolates the specific molecular mechanism.
| Evaluation Parameter | Generic Botanical Brokers | MedGence Precision Screening & CDMO | Value to Canadian Procurement |
|---|---|---|---|
| Constituent Identification | Basic TLC / UV-Vis spectrophotometry | High-Performance HPTLC, HPLC-DAD, LC-MS/MS | Prevents adulteration; immediate Health Canada NHP validation. |
| Contaminant Thresholds | Routine domestic market compliance | Heavy metals (ICP-MS), pesticide screening (USP <561>), aflatoxins | 100% adherence to Health Canada heavy metal & residual limits. |
| Potency Verification | Static ratio extracts (e.g., 10:1 crude) | Quantified marker active compound concentration (%) | Exact dosage efficacy for standardized finished capsules/tablets. |
| Traceability & Auditing | Paper-based trade intermediary documents | Complete digital batch records from cultivation base to shipment | Seamless pass during Health Canada Good Manufacturing Practices (GMP) reviews. |
We de-risk overseas sourcing by handling complex biological screening, regulatory dossier creation, pilot compounding, and bulk production under a single unified governance structure.
Our dedicated regulatory science department formulates comprehensive Drug Master Files (DMF), Master Production Documents, and product specifications mapped directly to Canadian eSTAR / NNHPD electronic licensing portals.
With integrated temperature-controlled logistics servicing major Canadian hubs (Vancouver, Toronto, Montreal), we offer DDP terms, customs compliance documentation, and warehousing buffers to buffer seasonal supply shocks.
Operating under strict dual-jurisdiction non-disclosure agreements (NDAs) and proprietary process ring-fencing, proprietary extraction parameters and client formulations remain strictly protected intellectual property.
Clear, technically rigorous answers concerning screening turnarounds, assay certifications, and international shipping to Canadian laboratories.
From single herb fingerprint identification to comprehensive Phase I-IV clinical trial data development, access our proven end-to-end pharmaceutical-grade natural product catalog.
